AstraZeneca’s Tagrisso plus chemotherapy improves overall survival in EGFR-mutated advanced lung cancer
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
This marks the fourth acquisition by Corona Remedies from multinational corporations
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
Subscribe To Our Newsletter & Stay Updated